Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

ClinicalTrials.gov ID: NCT00004196

Public ClinicalTrials.gov record NCT00004196. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients With Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy

Study identification

NCT ID
NCT00004196
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
University of Alabama at Birmingham
Other
Enrollment
3,000 participants

Conditions and interventions

Interventions

  • recombinant interferon alfa Biological
  • lymphangiography Procedure
  • Observation Drug

Biological · Procedure · Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 1999
Primary completion
Sep 30, 2004
Completion
Oct 31, 2007
Last update posted
Jan 19, 2014

1999 – 2007

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama 35294-3300
James Graham Brown Cancer Center at University of Louisville Louisville Kentucky 40202
Cancer Institute of New Jersey New Brunswick New Jersey 08903
Roswell Park Cancer Institute Buffalo New York 14263-0001

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00004196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2014 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00004196 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →